SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

Dog (Bitcoin) ($DOG.X) is trending as community members highlight its fair distribution and status as a Bitcoin-native meme coin launched via Runes. Many see $DOG.X as a way to onboard more users to Bitcoin, emphasizing its strong community and decentralized nature. Some community members are comparing it to $DOGE.X and anticipating a similar parabolic run.

DMTC or DIAMOND The Cat Coin is a viral meme coin on Solana Blockchain, Based in Thailand and Global and Based on a true story about my lovely cat(DIAMOND) and made by love, I just want my cat to be immortal in this whole world until I die that's a first idea of this project start. We're start from $2,000 Market cap and hit All time high at $10.9 million, please come to check our project and let's DMTC get list on Coingecko to let's everyone in this whole world know DMTC.

DIAMOND The Cat Coin

DIAMOND The Cat Coin ($DMTC.X) is gaining attention, with community members highlighting accumulation and potential for a breakout. Discussions center on its strong chart and the expectation of significant upward movement, with many using terms like "rocket" and "moon mission" to describe its potential. Community members suggest early entry for optimal gains.

"What's Updog?" is a Community Led token.

UpDog

UpDog is trending as the community rallies behind its purpose as a meme coin with a charitable component, donating to dog shelters. Conversations highlight the project's commitment and frequent donations as milestones are achieved. The coin, built on Solana, is also getting attention for its presence on the Jupiter Strict List.

What Is Pi Network? Pi Network is a social cryptocurrency, developer platform, and ecosystem designed for widespread accessibility and real-world utility. It enables users to mine and transact Pi using a mobile-friendly interface while supporting applications built within its blockchain ecosystem.  Supply Model and Mining Mechanism The Maximum Supply of Pi is 100 billion tokens. The Maximum Supply is comprised of the following: 65 Billion tokens (or 65%) are allocated for all community mining rewards; 10 billion (10%) are allocated for foundation reserves; 5 billion (5%) are allocated for liquidity purposes; and 20 billion (20%) are allocated for the Core Team. Each allocation mentioned above tracks the community Migrated Mining Rewards issuance pace, so the proportions of each allocation in the total supply remains the same at any given time.   The Effective Total Supply of Pi—the total Pi supply at the current time—allocates Pi proportionally the same as the Maximum Supply. Since every allocation tracks the Migrated Mining Rewards of the community, the Effective Total Supply can be calculated by dividing the current Migrated Mining Rewards of Pi on the Mainnet blockchain by 65%. The other allocations within the Effective Total Supply can then be calculated based on the same proportions as the Maximum Supply, e.g. at most 10% of the Effective Total Supply is available in the foundation reserve, 5% of the Effective Total Supply is available for liquidity purposes, and 20% of the Effective Total Supply is available for the Core Team. This remains true despite the fact that all tokens were minted at the genesis as technically required by the blockchain protocol.  Circulating Supply includes all Migrated Mining Rewards and all tokens that entered circulation from other buckets of the allocations, which at its maximum could be summed up to equal the Effective Total Supply.   Pi’s mining rewards are distributed based on an issuance formula that follows a declining exponential model defined in the Pi whitepaper. Users can increase the amount of mining rewards they receive based on their individual contributions to the network, like Security Circles, using utility-based Pi apps, running Nodes, etc. For each month, the amount of Pi to be distributed as mobile balance is capped and determined by the model, regardless of how many people or how many types of mining rewards there are during the month. The capping is achieved by the design of a system-wide base mining rate, and each type of mining rewards to each individual are just a multiplier of this base mining rate. As the monthly supplies always diminish, the base mining rate generally decreases over time.   Fewer Pi may also be issued because the real Pi issuance on the blockchain depends on Pioneers passing KYC and completing all steps required for migration to the Mainnet. Despite all efforts to facilitate and remind Pioneers to complete those required steps, there are always dropoffs along the way, resulting in less than all outstanding mobile balances to be issued on the blockchain. Because of this mechanism, the community issued amount (Migrated Mining Rewards) on the blockchain will likely be closer and closer to a line lower than the 65 billion. This is thus the reason for the variable Effective Total Supply which incorporates this effect. Effective Total Supply results from all Migrated Mining Rewards divided by 65%, as opposed to the Maximum Supply of 100 billion.  Ecosystem and Adoption Pi Network has built an integrated ecosystem that facilitates real-world transactions and decentralized applications. Pi can be used as a medium of exchange for goods and services, including online commerce and local brick-and-mortar businesses.  Users can engage with Core Team and community-built apps in the Pi ecosystem through the Pi Browser, where integrated features like the Pi Wallet provide a seamless experience. Events like PiFest 2024 showcased Pi’s growing adoption, with over 27,000 active sellers and 28,000 test merchants across 160 countries.  Who Are the Founders of Pi Network? Pi Network was founded by Dr. Nicolas Kokkalis and Dr. Chengdiao Fan, both of whom have PhDs from Stanford University and a passion for improving human lives through technology.  Dr. Nicolas Kokkalis is a Stanford PhD in EE and postdoc in CS with research on distributed systems and human-computer interaction. His work focuses on combining distributed systems and human computer interaction to bring cryptocurrency to everyday people. As a strong and long-term believer of the technical, financial and social potential of cryptocurrencies, he is determined to move them beyond their current limitations and is committed to bringing the power of blockchain to more people.  Dr. Chengdiao Fan holds a Stanford PhD in Anthropological Sciences, harnessing social computing to unlock human potential on a global scale. Chengdiao is building Pi Network to mobilize individuals all over the world to participate and be rewarded for their contributions, and establish an inclusive ecosystem for global citizens to unleash and capture their own agency, and in turn create utilities and productions for society and the world.  Compliance and Identity Verification Pi Network follows a one-account-per-person policy through its Know Your Customer (KYC) solution. This system combines machine automation and human verification to authenticate user identities while preserving privacy.  The KYC process emphasizes real individuals, combats fraudulent activities and enables fair participation in the mining process of the network. Pi’s identity verification approach balances scalability, security, and accessibility, allowing millions of users worldwide to validate their accounts while maintaining regulatory compliance.

Pi Network

Pi Network is trending as the community discusses the upcoming expiration of the KYC grace period and its potential impact on the circulating supply. Some users express frustration with unverified balances, while others remain optimistic about the project's long-term vision and increasing adoption. Discussions also cover potential listings and new developments within the Pi ecosystem.

“$PIXIE is the original Bitcoin Fairy mascot brought to life on Solana. First hidden on Bitcoin.org since 2009, Pixie represents one of the earliest and most authentic memes in crypto history. This project is fully community-driven and built with transparency, with supply locks, open communication, and a clear roadmap. The goal is to grow $PIXIE into the billions by combining strong branding, continuous marketing, and community power — not just as a meme, but as a long-term movement.”

Bitcoin's Fairy Mascot

PIXIE.X is trending as social media buzz positions it as a potential mascot for Bitcoin. Community members are actively discussing its potential role and integration within the broader cryptocurrency ecosystem.

Lyft, Inc. engages in the provision and management of an online social rideshare community platform. It offers access to a network of shared bikes and scooters for shorter rides and first mile and last-mile legs of multimodal trips, information about nearby public transit routes, and Lyft Rentals to offer riders a view of transportation options when planning any trip. The company was founded by Marcus Cohn, John Zimmer, Rajat Suri, Matt van Horn, and Logan Green in 2007 and is headquartered in San Francisco, CA.

Lyft Inc - Ordinary Shares Cls A

Lyft Inc

Lyft is trending due to its autonomous vehicle initiatives, including a robotaxi pilot in Atlanta and future projects with May Mobility and Mobileye, although some are concerned about the expensive timelines and heavy capital investment involved. The community is also discussing Lyft's valuation relative to Uber, potential for a short squeeze, and recent news regarding a share buyback and convertible bond offering. Bullish investors point to Lyft's first year of GAAP profitability and significant free cash flow as signs of a turnaround.

ZoraAI agents are designed to take the complexity out of everyday tasks, leaving you with more time and energy to focus on what matters most. With their powerful automation and adaptability, your life and work will become more efficient and effortless. With ZoraAI, you’re in control. The customizable agents feature lets you mix and match your favorite tools and capabilities from different agents to build one that’s perfectly tailored to your needs. Whether you want a multitasking powerhouse or a focused specialist, your personalized agent is designed to work exactly how you want it to—no coding required.

Zoracles

Zoracles ($ZORA.X) is trending due to recent price volatility, leading to active discussions about potential breakouts and resistance levels within the community. Some traders believe it's primed for a significant move, drawing comparisons to similar tokens, while others express concerns about its ability to sustain gains. The community speculates on the impact of potential FED rate cuts and overall market sentiment on altcoins.

Zcash is a decentralized and open-source cryptocurrency that offers privacy and selective transparency of transactions. Zcash payments are published on a public blockchain, but the sender, recipient, and amount of a transaction remain private.  Zcash is based on peer-reviewed cryptographic research, and built by a security-specialized engineering team on an open source platform based on Bitcoin Core's battle-tested codebase. Our improvement over Bitcoin is the addition of privacy. Zcash uses advanced cryptographic techniques, namely zero-knowledge proofs, to guarantee the validity of transactions without revealing additional information about them.  How Zcash works  Zcash encrypts the contents of shielded transactions. Since the payment information is encrypted, the protocol uses a novel cryptographic method to verify their validity.  Zcash uses a zero-knowledge proof construction called a zk-SNARK, developed by our team of experienced cryptographers based on recent breakthroughs in cryptography. These constructions allow the network to maintain a secure ledger of balances without disclosing the parties or amounts involved. Instead of publicly demonstrating spend-authority and transaction values, the transaction metadata is encrypted and zk-SNARKs are used to prove that nobody is cheating or stealing.  Zcash also enables users to send public payments which work similarly to Bitcoin. With the support for both shielded and transparent addresses, users can choose to send Zcash privately or publicly. Zcash payments sent from a shielded address to a transparent address reveal the received balance, while payments from a transparent address to a shielded address protect the receiving value.   Check out CoinBureau for guide on What is ZCash.

Zcash

Zcash is trending as community members discuss its potential, particularly highlighting its privacy features and recent technical developments, such as the Zashi wallet updates. Some believe ZEC.X is undervalued and poised for a significant uptrend, drawing comparisons to Bitcoin while emphasizing the importance of shielded transactions in a world where privacy is increasingly valued. Others point to its upcoming halving event as a potential catalyst for price appreciation.

Constellation Energy Corp. engages in the generation, supply, and marketing of clean electricity, and renewable energy products and solutions. The firm also offers wholesale energy, retail products and services. It operates under the following geographical segments: Mid-Atlantic, Midwest, New York, Electric Reliability Council of Texas (ERCOT), and Other Power Regions Segment. The company was founded in 1960 and is headquartered in Baltimore, MD.

Constellation Energy Corporation

Constellation Energy Corp

Constellation Energy is trending due to increasing investor interest in nuclear energy solutions for AI and data centers, with potential government support possibly on the horizon. The community is discussing the company's strategic partnerships and expansion efforts, along with considerations regarding its premium valuation, but several analysts remain bullish on the stock's prospects. Some see it as a way to capitalize on the growing demand for reliable, carbon-free baseload power.

Dogelon Mars

Dogelon Mars is trending as the meme coin market experiences renewed interest, with community members speculating on potential catalysts and upcoming developments. While some express frustration with the token's performance, others remain optimistic, citing long-term potential and the possibility of a significant price surge. Integration with X and comparisons to other dog-themed meme coins are also part of the conversation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

RCKT Stock Rises as FDA Lifts Clinical Hold on Danon Disease Study

Rocket Pharmaceuticals' shares soar as the FDA lifts its clinical hold on the pivotal Danon disease gene therapy study.

Citi said on Wednesday that the U.S. Food and Drug Administration may take a “more comprehensive look” at the level of immunomodulation required for Sarepta Therapeutics' gene therapy (SRPT) Elevidys.The FDA may determine that additional steps beyond Siromilus are recommended or required for non-ambulatory Duchenne muscular dystrophy (DMD) patients on Elevidys, Citi said, as per TheFly. Siromilus belongs to a group of medicines known as immunosuppressive agents and has shown promise in managing certain aspects of liver disease and its complications.Citi has a ‘Sell’ rating and a $14 price target on <a href="https://stocktwits.com/symbol/SRPT">Sarepta</a> shares. On Stocktwits, retail sentiment around Sarepta fell from ‘bullish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.<figure class="image"><img style="aspect-ratio:563/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_20_at_2_11_08_PM_png_5b28899976.webp" alt="SRPT's Sentiment Meter and Message Volume as of 2:11 p.m. ET on Aug. 20, 2025 | Source: Stocktwits" width="563" height="64"><figcaption>SRPT's Sentiment Meter and Message Volume as of 2:11 p.m. ET on Aug. 20, 2025 | Source: Stocktwits</figcaption></figure>Citi made the observations in light of the FDA’s recommendations for Rocket Pharmaceuticals (RCKT) made public earlier in the day.Rocket <a href="https://stocktwits.com/news-articles/markets/equity/why-is-rocket-pharma-stock-trading-higher/chsinTRRdhI">said</a> earlier on Wednesday that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on its mid-stage study of RP-A501 for the treatment of Danon disease. The hold, imposed roughly three months ago following the death of a patient in the trial, was lifted after Rocket satisfactorily addressed issues outlined in the clinical hold, the company said.The agency allowed the trial to resume at an adjusted dose of RP-A501 in three patients, with a minimum four-week interval between dosing and with an immunomodulatory regimen more closely reflecting the one administered in an early-stage study pediatric cohort.Sarepta, like Rocket Pharma, has been plagued by patient deaths. It's gene therapy, Elevidys, a medicine intended for the treatment of Duchenne muscular dystrophy (DMD), created safety concerns following the death of two patients after treatment earlier this year. Both non-ambulatory patients suffered from acute liver failure.Sarepta has now resumed shipments for ambulatory individuals after a temporary pause initiated in late July. The company is now working with the FDA on the safety labelling process and risk-mitigation approach for non-ambulatory individuals.SRPT stock is down by 83% this year and by about 86% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/regeneron-says-fda-will-take-more-time-to-review-its-two-eylea-hd-submissions/chsitx3Rdht">Regeneron Says FDA Will Take More Time to Review Its Two Eylea HD Submissions</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration a Sarepta Therapeutics logo is seen on a smartphone and a pc screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Citi Believes FDA May Closely Watch Sarepta’s Safeguards For Gene Therapy In Non-Ambulatory DMD Patients

The firm said that the FDA may determine that additional steps beyond Siromilus are recommended or required for non-ambulatory Duchenne muscular dystrophy patients on Elevidys. 

Equity

Rocket Pharmaceuticals, Inc. (RCKT) on Wednesday said that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on its mid-stage study of RP-A501 for the treatment of Danon disease.The hold, <a href="https://stocktwits.com/news-articles/markets/equity/rckt-stock-downgraded-after-patient-death-but-retail-bullish/ch0oee8RbrA">imposed</a> roughly three months ago following the death of a patient in the trial, was lifted after Rocket satisfactorily addressed issues outlined in the clinical hold, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.rocketpharma.com/news-releases/news-release-details/rocket-pharmaceuticals-announces-fda-has-lifted-clinical-hold">said</a>. The agency authorized the study to resume with an adjusted dose of the investigational gene therapy.Rocket Pharma stock shot up 25% in Wednesday’s pre-market session following the development. On Stocktwits, retail sentiment around RCKT rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume rose from 'low' to 'normal' levels.&nbsp;Danon disease is a rare, genetic disorder primarily affecting the heart, skeletal muscles, and sometimes the brain. It's characterized by weakening of the heart muscle, muscle weakness, and intellectual disability.Following the death of a patient, Rocket paused further dosing in the mid-stage study, and on May 23, the FDA placed a clinical hold on the trial to allow for further evaluation. The trial can now resume at an adjusted dose of RP-A501 in three patients, with a minimum four-week interval between dosing, followed by additional patients to complete the trial. The low dose has been determined as most likely to confer the safety and efficacy identified in the low-dose early-stage study cohorts, the company said.Rocket also said that it will collaborate with investigators to implement an immunomodulatory regimen more closely reflecting the one administered in the early-stage study pediatric cohort. Further updates about the mid-stage study can be expected following review of data from the next three patients, the company said.RCKT stock is down by 77% this year and by about 85% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-freezes-hiring-to-cut-costs-says-report/chsinAURdhO">Novo Nordisk Freezes Hiring To Cut Costs, Says Report: Retail Sees Stock Surpassing $100-Mark In A Year</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Why Is Rocket Pharma Stock Up 25% Pre-Market Today? 

The U.S. Food and Drug Administration has lifted the clinical hold on the company’s mid-stage study of RP-A501 for the treatment of Danon disease.

RCKT Stock Up on FDA's RMAT Tag to Gene Therapy for Heart Failure

Rocket Pharmaceuticals jumps 16.8% as FDA grants RMAT status to RP-A601 on positive phase I heart disease data.

RCKT's IND for RP-A701 in Dilated Cardiomyopathy Gets FDA Clearance

FDA clears Rocket Pharmaceuticals' IND for RP-A701, advancing its gene therapy for BAG3-linked dilated cardiomyopathy.

RCKT Stock Tanks on Patient Death in Danon Disease Study

Wall Street analysts issued a fresh round of ratings changes on Wednesday, including notable upgrades for State Street (STT) and FICO (FICO) and downgrades for Booz Allen (BAH) and Rocket Pharmaceuticals (RCKT), according to TheFly.Top 3 Upgrades:State Street received an upgrade from Truist, raising the stock to ‘Buy’ from ‘Hold’ and increasing its price target to $112 from $85. The brokerage sees the company as the biggest beneficiary among trust banks from the recent equity market rebound.<a href="https://stocktwits.com/symbol/STT">State Street’s stock</a> was up 0.71% in morning trade on Wednesday.JPMorgan upgraded Vail Resorts’ (MTN) shares to ‘Neutral’ from ‘Underweight,’ keeping the $167 target, citing improved risk-reward at current levels.&nbsp;The upgrade comes after the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/vail-resorts-brings-back-longtime-ceo-rob-katz/ch0odyHRbrF">announced</a> on Tuesday that Rob Katz will return as CEO, effective immediately, replacing Kirsten Lynch, who has served as chief executive for three years.<a href="https://stocktwits.com/symbol/MTN">Vail Resorts’ stock</a> rocketed 14.44% in morning trade on Wednesday.Baird shifted its outlook on FICO’s shares to a more bullish stance, raising the stock to ‘Outperform’ from ‘Neutral’ but with a lower price target of $1,900, down from $2,021. The brokerage said the stock’s recent sell-off, tied to regulatory risk, creates upside potential.<a href="https://stocktwits.com/symbol/FICO">Fico’s stock</a> traded up 6.3%&nbsp;on Wednesday morning.Top 3 Downgrades:Goldman Sachs cut its&nbsp;rating on Booz Allen’s stock to ‘Sell’ from ‘Neutral,’ trimming the price target to $94 from $108, citing limited medium-term growth and downside valuation risk.<a href="https://stocktwits.com/symbol/BAH">Booz Allen’s stock</a> fell 2.24% in morning trade on Wednesday.Meanwhile, TD Cowen downgraded Freshpet (FRPT) shares to ‘Hold’ from ‘Buy’, maintaining a price target of $96. The brokerage said slowing retail sales growth triggered the call.<a href="https://stocktwits.com/symbol/FRPT">Freshpet’s stock</a> was down 4.18%&nbsp;on Wednesday morning.&nbsp;Jefferies slashed its rating on Rocket Pharmaceuticals stock to ‘Hold’ from ‘Buy’ and the price target to $2.50 from $29, citing an FDA&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rckt-stock-downgraded-after-patient-death-but-retail-bullish/ch0oee8RbrA">clinical hold</a> on a key gene therapy trial.&nbsp;<a href="https://stocktwits.com/symbol/RCKT">Rocket Pharmaceutical’s</a> stock was up 3.6% at the start of Wednesday’s session despite the bearish outlook.The broader market traded in the red as investors watched for Nvidia’s (NVDA) earnings after the closing bell. The SPDR&nbsp;<a href="https://stocktwits.com/symbol/SPY">S&amp;P 500</a> ETF Trust (SPY) fell 0.14%, and the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ</a> Trust (QQQ), which tracks the Nasdaq 100, edged 0.04% lower. The SPDR&nbsp;<a href="https://stocktwits.com/symbol/DIA">Dow Jones Industrial Average</a> ETF (DIA) was down 0.1%.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/game-stop-stock-climbs-after-first-ever-bitcoin-buy-worth-half-a-billion/ch0oSz2RbsX">GameStop Stock Declines After First-Ever Bitcoin Buy Worth Half A Billion</a>

The Wall Street Bull statue in Manhattan. (Photo by Erik McGregor/LightRocket via Getty Images)

Booz Allen, FreshPet, Rocket Pharma Downgraded, While Vail Resorts And FICO Get An Upgrade – Top Wall Street Analyst Calls Today

State Street received an upgrade from Truist, raising the stock to ‘Buy’ from ‘Hold’ and increasing its price target to $112 from $85.

Rocket Pharmaceuticals (RCKT) plunged nearly 63% on Tuesday, hitting an all-time low after the U.S. FDA placed a clinical hold on its gene therapy trial, RP-A501, for Danon disease following the&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/fda-pauses-rocket-pharmaceuticals-gene-therapy-trial-after-patient-death/ch0V9xRRbrR">death</a> of a patient.The selloff marked the company's worst session on record.&nbsp;Despite the steep decline, retail investor sentiment remained notably bullish. Message volume on Stocktwits spiked to ‘extremely high’ levels, and the ticker added 20% more watchers&nbsp;over the past 24 hours — the highest among healthcare stocks on Tuesday.<h3>Wall Street Turns Cautious</h3>According to The Fly, the incident prompted a wave of downgrades from major analysts:<ul style="list-style-type:circle;"><li>Morgan Stanley cut RCKT to 'Equal Weight' from 'Overweight' and slashed its price target from $42 to $7, which still implies more than 200% upside from current levels.</li><li>Leerink lowered its rating to 'Market Perform' from 'Outperform' with a new target of $8. The firm cited three overhangs: safety concerns, shaken investor confidence, and financial pressure.</li><li>TD Cowen downgraded the stock to 'Hold' from 'Buy,' citing unresolved safety risks related to thrombotic microangiopathies that preceded the addition of the C3 inhibitor.</li><li>Needham also moved to 'Hold' from 'Buy' and withdrew its $42 target, calling RP-A501 the company's "main value driver" but now fraught with uncertainty.</li></ul><h3>Retail Shrugs Off Worries</h3>Despite the institutional pullback, retail traders doubled down. Stocktwits sentiment turned 'extremely bullish,' with many users arguing that Rocket's broader pipeline remains compelling.<figure class="image"><img style="aspect-ratio:1322/862;" src="https://news.stocktwits-cdn.com/RCKT_chart_with_sentiment_meter_and_message_volume_as_of_May_27_png_0e99f740f3.webp" alt="RCKT chart with sentiment meter and message volume as of May 27.png" width="1322" height="862"><figcaption>RCKT chart with sentiment meter and message volume as of May 27. | source: Stocktwits</figcaption></figure>One optimist expects the stock to be "back over $4.50 (maybe $5) within 3 months."<stembedurl>https://stocktwits.com/srick2000/message/615977188</stembedurl>"For one moment, ignore the CV gene therapy, which is the cause of today's drop, and just look at the rest of the pipeline here. Particularly late-stage hematology," posted another, citing the firm's leadership, including CCO &amp; CMO Sarbani Chaudhuri, formerly with Johnson &amp; Johnson.<stembedurl>https://stocktwits.com/geegor/message/615978028</stembedurl>RCKT shares gained about 3% in after-hours trading following the plunge in the regular session.The episode echoes a March setback for&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sarepta-therapeutics-stock-has-a-nightmarish-week-after-dmd-patient-death/ch78AvoRbPU">Sarepta Therapeutics</a> (SRPT), when a patient receiving its approved Duchenne muscular dystrophy therapy died from liver failure.&nbsp;As Barron's&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.barrons.com/articles/gene-therapy-trial-death-rocket-stock-7aee984c?mod=md_stockoverview_news">noted</a>, such high-profile incidents have made gene therapy stocks increasingly unpalatable for many investors, despite the field's early promise.<a href="https://stocktwits.com/symbol/RCKT">Rocket Pharma shares</a> are now down over 80% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Trader watching stocks crash on screen - stock photo. 

Patient Death In Rocket Pharma Trial Triggers Downgrades, But Retail Traders Bet Big On Strong Recovery

Message volume on Stocktwits spiked to ‘extremely high’ levels, and the ticker added 20% more watchers.

Shares of Rocket Pharmaceuticals, Inc. (RCKT) traded 64% lower in Tuesday’s pre-market trading session after the U.S. Food and Drug Administration (FDA) <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.rocketpharma.com/news-releases/news-release-details/rocket-pharmaceuticals-provides-update-phase-2-clinical-trial-rp">placed</a> a clinical hold on its trial related to investigational gene therapy for Danon disease called RP-A501, following the death of a patient.The patient was part of the Phase 2 trial of RP-A501. They experienced an unexpected Serious Adverse Event (SAE) involving clinical complications related to a capillary leak syndrome (CLS), which led to their passing.CLS is a condition where fluid and proteins leak out of the small blood vessels and into surrounding tissues, causing dangerously low blood pressure, fluid buildup in the body, and other complications.Rocket Pharma said it is conducting a comprehensive root cause analysis and is in active dialogue with the FDA.While the company voluntarily paused dosing in the study after the death of the patient, the FDA on May 23 also placed a clinical hold on the trial to allow further evaluation, the company said.Rocket Pharmaceuticals said that it is working with the FDA to ensure the safety of all study patients and resume the trial “as expeditiously as possible,” but stopped short of providing a timeline for the resumption of trials.The company also said that it expects its existing resources to be sufficient to fund operations into 2027. Rocket had cash, cash equivalents, and investments of $318.2 million at the end of the first quarter.On Stocktwits, retail sentiment around Rocket Pharmaceuticals jumped from ‘bearish’ to ‘extremely bullish’ territory while message volume rose from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:626/65;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_27_at_8_29_26_AM_png_8a7c609af6.webp" alt="RCKT's Sentiment Meter and Message Volume as of 8:30 a.m. ET on May 27, 2025 | Source: Stocktwits" width="626" height="65"><figcaption>RCKT's Sentiment Meter and Message Volume as of 8:30 a.m. ET on May 27, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user opined that the drop in share price over the news could result in a strong entry point.<stembedurl>https://stocktwits.com/TheCatalystCalendar/message/615894941</stembedurl><a href="https://stocktwits.com/symbol/RCKT">RCKT stock</a> is down by over 50% this year and more than 70% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/sanofi-vnvc-open-vaccine-manufacturing-in-vietnam/ch0VBtPRbrb">Sanofi, VNVC Launch Vaccine Manufacturing Facility In Vietnam, Says Report: Retail’s Positive</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Rocket Pharmaceuticals Stock Drops Pre-Market After FDA Pauses Gene Therapy Trial Over Patient Death: Retail Turns Bullish

Rocket Pharmaceuticals said that it is working with the FDA to ensure safety of all study patients and resume the trial “as expeditiously as possible."

Rocket Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today...

Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector and adeno-associated viral vector gene therapy platforms. Its clinical program is an LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded on July 7, 1999 and is headquartered in Cranbury, NJ.

RCKT
Rocket Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest RCKT News

RCKT Rocket Pharmaceuticals Inc